Aptamer Group partners with top five global pharmaceutical company to support innovative vaccine development
Back

16th July 2021

Aptamer Group partners with top five global pharmaceutical company to support innovative vaccine development

Aptamer Group Limited, the developer of Optimerâ„¢ therapeutics and diagnostics, has secured a contract with a top five global pharmaceutical company to develop Optimers to support the development of a novel vaccine candidate for neurodegenerative disease.

 

 

The agreement includes an initial upfront payment to Aptamer Group with long term recurring licensing fees for over 10 years upon implementation of the assay into the partner’s global vaccine manufacturing processes.

Aptamer Group will isolate Optimer reagents and incorporate them into an analytical assay with the aim of enabling the vaccine candidate currently in clinical trials to achieve regulatory compliance. The Optimers will be used to develop a potency assay for essential evaluation of the final vaccine. The Optimer reagents are expected to help overcome cross-reactivity issues and allow specific detection and quantification of the active vaccine component within the vaccine additives.

To read the full story, please visit the Aptamer Group website.